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Primary apocrine sweat gland carcinoma (PASGC) is an extremely rare malignancy with a relatively favorable prognosis.
PASGC is often suspected to be a benign disease during an initial clinical examination, which leads to inadequate initial
treatment and extensive metastasis. Owing to the limited number of reports on PASGC, its diagnostic criteria and
treatment guidelines have not yet been established. The only known curative therapy for localized PASGC is wide local
excision. In the present report, we describe two cases of PASGC with locally aggressive disease that arose in the axilla
and review the literature about its clinicopathological features, diagnosis, and treatment. Based on the findings of the
current report, we suggest that a sentinel lymph node biopsy and adjuvant anti-estrogen therapy should be included
in the management of PASGC.
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Primary apocrine sweat gland carcinoma (PASGC) is a
rare subtype of sweat gland carcinoma, with approxi-
mately 50 cases reported in the literature thus far [1-5].
It occurs mostly in apocrine-dense regions such as the
axilla and anogenital areas, although it has also been
reported to occur in less typical locations such as the
forehead, wrists, ear canals, eyelids, trunk, feet, toes, and
fingers [1-6]. This disease presents in older patients,
with a median age at presentation of 67 years. No racial
or gender differences in PASGC incidence have been re-
ported. The incidence of PASGC is quite low at 0.0049
to 0.0173 cases/100,000 persons per year [1]. Most
PASGCs are generally characterized by indolent symp-
tomatic progression and a slow growth rate and are not
clinically suspected prior to biopsy. Once the diagnosis
is made, the treatment of choice for localized PASGC is
wide local excision with a clear margin of 1 to 2 cm,
along with axillary lymph node dissection if clinically
positive nodes are detected [1-5,7]. The benefit of* Correspondence: mklegend0@gmail.com
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unless otherwise stated.adjuvant chemotherapy for PASGC with or without
lymph node metastases remains controversial. However,
adjuvant radiotherapy may be recommended for locally
advanced disease [7]. Although PASGC has a high inci-
dence of local recurrence and regional lymph node metas-
tasis, most patients have an indolent disease course. Only
14 cases of PASGC with distant metastasis to the lungs,
liver, or bone have been reported to date [2]. In the largest
retrospective cohort study of PASGC, the median overall
survival and 5-year disease-specific survival rate were
51.5 months and 88%, respectively [1]. The prognostic
factors for PASGC are difficult to identify because of
the small number of reported cases, but the possible fac-
tors include tumor size, histological type, lymph node in-
volvement, and distant metastasis [4,5]. Here, we report
two cases of locally advanced PASGC that arose in the
axilla, which is the most common site of PASGC. We
also present a summary of the clinicopathological fea-
tures, diagnosis, and treatment based on a review of the
literature.Case presentation
Case 1
A 51-year-old man with a 5-mm-sized skin lesion in the
right axilla was examined by a dermatologist in OctoberThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(hidradenitis suppurativa). In December 2013, the pa-
tient was referred to the clinic of the Department of
Surgery for excisional biopsy of the axillary mass, which
had been growing rapidly over the previous 3 months.
The patient had no symptoms or any medical or familial
history of malignancy. On physical examination, a 4 ×
3 cm-sized, erythematous, indurated, non-tender, and
multilobular subcutaneous mass was palpated in the
left axilla (Figure 1). Physical examination of the bilat-
eral breast and contralateral axilla yielded unremarkable
results. The mass was suspected to be a benign skin tumor
and was completely excised and sent for histopathological
examination. Macroscopic examination of the excised spe-
cimen revealed a 2 × 2 cm-sized tumor with a reddish
colored cut surface. Microscopically, the malignant cells
contained periodic acid-Schiff (PAS)-positive cytoplasmic
granules, abundant eosinophilic cytoplasm, and apocrine-
like decapitation (Figure 2A). On immunohistochemical
staining, the tumor cells were positive for gross cystic dis-
ease fluid protein (GCDFP)-15 (Figure 3A), cytokeratin
(CK) 7, and epithelial membrane antigen (EMA), and
negative for CK20, S-100 protein, estrogen receptor (ER),
and progesterone receptor (PR) (Table 1). Based on these
findings, the preliminary pathological diagnosis was
carcinoma with apocrine differentiation. To exclude other
possible primary tumors, clinical evaluations including
positron emission tomography-computed tomographyFigure 1 A photograph of the left axillary mass prior to excision.
The mass, measuring 3 × 3 cm in size, was firm, erythematous,
multilobular, indurated, and non-tender.(PET-CT), chest CT, abdominal and pelvic CT, colonos-
copy, and duodenoscopy were performed, and no other
occult potential primary site was identified. The diagnosis
of PASGC was verified based on the pathologic features
and the lack of any clinical evidence for a tumor originat-
ing from another site. PET CT and chest CT were per-
formed 12 days after the initial excisional biopsy, and their
findings were indicative of persistent disease in the right
axilla. We therefore performed complete (including level
III) axillary lymph node dissection and further excision of
the involved margins. The final pathologic result included
a 0.7 × 0.3 cm-sized residual carcinoma and metastasis in
50 dissected lymph nodes, including two level III lymph
nodes. The patient underwent adjuvant radiation therapy
to the right axilla and supraclavicular regions, with 50 Gy
in 25 fractions over a period of 5 weeks. Radiation therapy
was delivered using three-dimensional conformal radio-
therapy with 10-MV photons. There was no evidence of
recurrence 9 months after surgery.
Case 2
In November 2013, a 66-year-old man presented at our
institution with a slowly growing, painful mass in the
right axilla. The patient had been aware of the growing
mass over the previous year, but the absence of pain had
delayed his visit to the hospital. He had not experienced
pain until just before the hospital visit. The patient had a
medical history of endoscopic submucosal dissection for
early gastric cancer 2 years previously, but no other med-
ical or familial history of cancer. Physical examination re-
vealed an approximately 4 × 3 cm-sized, firm, reddish,
tender, indurated mass in the right axilla. No other lesions
were found in the breasts or the contralateral axilla. Based
on these clinical findings, a preliminary diagnosis of a be-
nign skin tumor was considered, and surgical excision of
the lesion was performed to determine the clinical diagno-
sis. Microscopically, the tumor cells contained enlarged
nuclei with prominent nucleoli and PAS-positive granules
and abundant eosinophilic cytoplasm with decapitation
secretion (Figure 2B). Immunohistochemical staining
revealed positive expression of GCDFP-15 (Figure 3B),
CD15, CK7, CK20, and EMA (Table 1). These findings
were consistent with those of carcinoma with apocrine
differentiation. An extensive workup including PET-CT,
chest CT, abdominal and pelvic CT, colonoscopy, and
duodenoscopy did not reveal any other lesions suggestive
of primary or secondary tumors, or any clinical evidence
of recurrent or metastatic gastric cancer. Apocrine breast
cancer was excluded on the basis of breast ultrasonog-
raphy findings. After excluding the possibility of any other
primary origin tumor through a complete clinical evalu-
ation, a diagnosis of PASGC was made. As there was evi-
dence of residual metastatic lymph nodes on the PET-CT
and chest CT scans obtained 13 days after the initial
Figure 2 Microscopic features of the tumor cells. (A, B) The tumor cells contained abundant, granular, eosinophilic cytoplasm and enlarged
nuclei with prominent nucleoli (hematoxylin and eosin stain, ×200).
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subcutaneous tissue, along with axillary lymph node dis-
section, was performed to obtain microscopically clear
margins. Axillary lymph node dissection was extended to
the level III nodes. Pathologic examination revealed no re-
sidual carcinoma in the primary tumor site; however, all
12 resected axillary lymph nodes, including two level III
lymph nodes, were found to contain metastases. The pa-
tient received adjuvant radiation therapy to the right axilla
and supraclavicular regions, with a total dose of 50 Gy in
25 fractions over a period of 5 weeks. Radiation therapy
was delivered using three-dimensional conformal radio-
therapy with both 4 and 10 MV. The patient had no evi-
dence of recurrence or metastasis during a 10-month
follow-up.
Conclusions
PASGC, a subtype of sweat gland carcinoma, is an ex-
tremely rare skin cancer [1-5]. Most cases of PASGC
present with slowly enlarging, painless, colorless or red-
dish, indurated nodules or plaques. They are often ini-
tially misdiagnosed as benign skin tumors because of
their indolent nature. In pathologic diagnosis, PASGC
should be distinguished from other skin cancers, meta-
static visceral adenocarcinomas, and breast carcinomas
with apocrine features [3,6-8]. Definite diagnostic criteria
for PASGC have not been established because of the
limited number of cases. Although the diagnostic criteriaFigure 3 Immunostaining for gross cystic disease fluid protein-15. (A,
was observed in the tumor cells (×200).for PASGC remain controversial, decapitation secretion
in eosinophilic epithelial cells is considered a key indica-
tor of apocrine differentiation [8]. In addition to this
essential feature, Paties et al. proposed the following
diagnostic criteria for PASGC: (1) decapitation secretion,
(2) PAS-positive diastase-resistant material in the cells
or lumina, and (3) positive immunostaining for GCDFP-
15 (even if focal) [9]. A number of other reports have in-
dicated that staining for CD15 and lysozyme may help
distinguish between PASGC and eccrine carcinoma [10]
and that androgen receptor positivity is strongly asso-
ciated with PASGC carcinoma [11]. Thus, immuno-
histochemical findings could be helpful in diagnosing
PASGC. However, given the lack of definite diagnostic
criteria, any other possible primary origin must be ruled
out through a full clinical workup before this malignancy
can be definitely diagnosed [2,7,8]. The standard treat-
ment for PASGC is wide local excision and regional lymph
node dissection for clinically positive nodes. Despite the
fact that regional lymph node metastases are found in
nearly 50% of patients with PASGC at the time of diagno-
sis, the benefit of performing prophylactic regional lymph
node dissection in patients with no clinical evidence of
lymph node metastasis remains controversial. Some stud-
ies have shown that prophylactic lymph node dissection
has no influence on survival or disease recurrence in
PASGC patients [2,4]. However, several case reports have
found that sentinel lymph node (SLN) biopsy is useful inB) Diffuse cytoplasmic staining of gross cystic disease fluid protein-15
Table 1 Histological and immunohistochemical details of
the two cases
Case 1 Case 2
PAS staining of diastase-resistant
granules
Tumor cell focal (+) Tumor cell focal (+)
Secretion (+) Secretion (+)
Eosinophilic cytoplasm + +











P53 Focal (+) Focal (+)
CEA − Focal (+)
CEA, carcinoembryonic antigen; CK, cytokeratin; EMA, epithelial membrane
antigen; ER, estrogen receptor; GCDFP-15, gross cystic disease fluid protein-15;
HER2, human epidermal growth receptor 2; PAS, periodic acid-Schiff; PR,
progesterone receptor; SMA, smooth muscle actin.
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opsy may be helpful in assessing regional nodal status
and decision-making regarding lymph node dissection
in PASGC [12,13]. The role of postoperative adjuvant
treatment in PASGC remains unclear. Adjuvant chemo-
therapy is not routinely offered, because PASGC is gener-
ally considered resistant to chemotherapy [3,7]. However,
some case reports have described favorable responses to
various chemotherapeutic agents in patients with meta-
static PASGC [14-16], thus warranting further study.
Compared with chemotherapy, radiotherapy may cure the
disease or at least reduce the risk of relapse [7]. A marked
response to radiation therapy with a total dose of 50 Gy in
a patient with regional recurrence of PASGC has been re-
ported [17]. Furthermore, Chamberlain et al. suggested
that adjuvant radiotherapy should be considered if the dis-
ease has one or more of the following characteristics: large
tumor size (≥5 cm), positive resection margin, moderately
to poorly differentiated tumors, or vascular or lymphatic
invasion [7]. Interestingly, PASGCs often express ER and
PR, unlike most primary apocrine breast carcinomas [8].
The relatively frequent expression of these receptors may
provide a rationale for anti-estrogen therapy, by using
drugs such as tamoxifen. One case report described a
complete response to tamoxifen in a patient with ER-
positive metastatic PASGC [18]. In another case report,
adjuvant tamoxifen therapy resulted in a disease-free sur-
vival of over 3 years after surgery for recurrent PASGC[19]. Therefore, anti-estrogen therapy may be considered
not only for the treatment of metastatic PASGC but also
for the adjuvant treatment of PASGC.
Because of its rarity, isolated case reports have been
the main source of information regarding PASGC. Cur-
rently, there are no established guidelines for the man-
agement of this disease. Based on our literature review,
we recommend the following for the treatment of local-
ized PASGC: 1) a wide local excision with a 1- to 2-cm
clear margin, 2) regional lymph node dissection for clinic-
ally positive nodes, 3) SLN for clinically negative nodes,
4) adjuvant radiation therapy (owing to the high local
recurrence of this malignancy), and 5) adjuvant anti-
estrogen therapy in patients with hormone receptor-
positive tumors.
PASGC is a rare malignancy that arises from the sweat
glands, for which diagnostic criteria and treatment guide-
lines have yet to be established. We reviewed the literature
to identify clinicopathological characteristics that may
help diagnose PASGC. We have also made a number of
treatment recommendations for patients with PASGC, in-
cluding the use of sentinel lymph node biopsy and adju-
vant anti-estrogen therapy.
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